LOS ANGELES, July 12 /PRNewswire/ -- SIDMAP, the leading provider of tracer-based dynamic metabolic phenotyping services that help biotech and pharmaceutical companies improve the drug discovery process, today announced the opening of a new, state-of-the-art laboratory in West Los Angeles, California.
The lab provides additional space for SIDMAP researchers and scientists to conduct profiles in order to help clients more efficiently identify, select, and develop optimal disease targets, biomarkers, and drug candidates.
"Dr. Lee and I, and the growing team of researchers at SIDMAP, now have everything we need to continue providing excellent service to those interested in using our technology," said Dr. Laszlo Boros, SIDMAP's Chief Scientific Advisor. "The new laboratory has the latest gas chromatography instruments, mass spectrometers, and other equipment necessary to produce the highest quality results for our customers."
"We are excited at the prospect of making a significant contribution to the drug discovery process," said Agi Hirshberg, President and Founder of SIDMAP. "Considerable planning went into the design of the laboratory and we look forward to providing our clients with the critical information they need to enhance the drug and biomarker development processes."
For more information and visuals of the laboratory, visit http://www.sidmap.com.
SIDMAP provides metabolic phenotyping services to pharmaceutical, biotech and research organizations seeking to enhance the drug discovery and development process, and develop further insight into disease states. SIDMAP's unique, patent-pending tracer technology measures metabolic pathway flux to gain unique insight into cell function. A SIDMAP profile provides an accurate metabolic analysis of a compound's biological impact using both in vitro and in vivo systems, before a company spends millions on development and clinical trials. SIDMAP is headquartered in Los Angeles, California.